DNDi E-news
November 2014   |   View Online

Strengthening the malaria treatment arsenal for children in Africa

 

Viewpoint by Dr Bernhards Ogutu and Dr Sodiomon Sirima


Malaria is the leading parasitic cause of morbidity and mortality worldwide with African children under five years of age being the most severely affected. In 2012 alone, the disease killed an estimated 482,000 children: that is 1,300 children every single day. More »

Anti-Malarial ASMQ FDC: Safe and effective for young children in Africa


Results of a five-year-long clinical trial in three African countries in children under 5 years old with uncomplicated falciparum malaria show safety and efficacy of ASMQ FDC is not inferior to Artemether-Lumefantrine (AL) FDC. More »

Kala-azar treatments in Bangladesh: Study results support WHO recommendations


Clinical trial comparing efficacy and safety of short-course drug combinations (with AmBisome®, miltefosine, paromomycin) with AmBisome® alone against kala-azar in Bangladesh shows excellent cure rates and tolerability. More »

Prize for innovative cooperation model for malaria is awarded to DNDi in Brazil


The Funding Authority for Studies and Projects (FINEP) of Brazil’s Federal Government awards DNDi Latin America for its innovative cooperation model for developing ASMQ in Brazil with pharmaceutical company Farmanguinhos. More »

Bill & Melinda Gates Foundation announces USD 60 million grant to DNDi to fill R&D gaps


DNDi has been awarded USD 60 million by the BMGF towards its clinical development of new treatments for sleeping sickness, river blindness, and kala-azar. More »

DNDi signs strategic collaboration in Colombia


Ruta-N and DNDi establish a strategic alliance, with an initial contribution of USD 647,500. The joint programme begins with an evaluation of alternative topical therapies for cutaneous leishmaniasis. More »

Publications


Journal of Antimicrobial Chemotherapy:
Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis More »

Antimicrobial Agents and Chemotherapy:
Biomarkers to monitor therapeutic response in leishmaniasis: a systematic review More »

Journal of Biomolecular Screening:
Drug discovery for human African trypanosomiasis: Identification of novel scaffolds by the newly developed HTS SYBR Green assay for Trypanosoma brucei More »

Antiviral Therapy:
Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations More »

Health Affairs:
Improving access to malaria medicine through private-sector subsidies in seven African countries More »

European Journal of Pharmaceutical Sciences:
In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis More »
EN ESPAÑOL
DNDi gana el premio FINEP en Brasil »
DNDi firma colaboración estratégica en Colombia »

EM PORTUGUÊS
DNDi ganha prêmio FINEP no Brasil »
DNDi assina colaboração estratégica na Colômbia »
EVENTS

PAST EVENTS
JOBS

Legal Officer (short term) »
Coordinateur de la Plateforme THA »
DNDi IN THE MEDIA

PharmaTimes: "FDA priority review voucher scheme under fire"

El Mundo: "Firman alianza para estudio de enfermedades olvidadas"

Daily Nation: "New drug offers hope in fight against malaria"

Priorité Santé, RFI: "Résultats d’une étude antipaludique pour les enfants en Afrique"

Forbes: "Bill Gates Gives $500 Million To Fight Malaria, Other Diseases"

SciDev.net: "Médicos de América plantean acciones contra chagas a 2020"

El Mundo: "Cada vez más cerca la pomada contra la leishmaniasis"
 
SciDev.net: "UK universities to be scrutinised on global health research"
Follow us on social media:
Twitter Facebook LinkedIn YouTube
Visit our websites:
DNDi.org  DNDiAL.org  DNDiNA.org  DNDiJapan.org  
Copyright © 2014 Drugs for Neglected Diseases initiative (DNDi), All rights reserved.
You are receiving this email because you are part of DNDi's network. You have the option to unsubscribe.

Our mailing address is:
Drugs for Neglected Diseases initiative (DNDi)
15 ch. Louis-Dunant
Geneva 1202
Switzerland

Add us to your address book


unsubscribe from this list    update subscription preferences